Biopharmaceutical
Pharmaceutical
Health
Global Blood Therapeutics
$57.469876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$57.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.95 (1.68%) Today
$0.00 (0.00%) As of 3:46 PM EDT after-hours
Why Robinhood?
You can buy or sell GBT and other stocks, options, ETFs, and crypto commission-free!
About GBT
Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Read More It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
CEO
Employees
171
Headquarters
South San Francisco, California
Founded
2011
Market Cap
3.18B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
692.38K
High Today
$57.54
Low Today
$56.33
Open Price
$56.59
Volume
435.79K
52 Week High
$64.94
52 Week Low
$30.15
Collections
Biopharmaceutical
Pharmaceutical
Health
Therapy
Biotechnology
Medical
Technology
2015 IPO
Price Paid on Robinhood
29% Higher
Right Now
52 Week Low
$30.15
Average Price Paid
$44.38
52 Week High
$59.95
Analyst Ratings
86%
of 14 ratings
Buy
86%
Hold
14%
Sell
0%
GBT Earnings
-$0.94
-$0.89
-$0.83
-$0.78
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, After Hours